Exactly, I didn't actually realise the reimbursement difference was so large. I'm surprised doctors still even use stents, I guess Glaukos' enormous marketing budget still has a few doctors believing they're better. This recent change to reimbursement will definitely force doctors to have a look at the alternatives to stents, and I'm sure that once they've had a try at canaloplasty with the iTrack Advance they'll realise how much superior our device is compared to iStent.
We basically have the US government advertising iTrack Advance over stents as a result of this massive reimbursement change, which is definitely perfectly timed with the launch of iTrack Advance globally. Even in the scenario where iTrack Advance is inferior (which is certainly not the case), I would struggle to see how it wouldn't get a lot of sales purely thanks to reimbursement.
I'm definitely looking forward to December, not for Santa or Summer but for the big fat numbers I'm expecting EYE to release
Nova Eye Medical (EYE) Discussion, page-959
-
- There are more pages in this discussion • 2,229 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add EYE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
18.0¢ |
Change
0.005(2.86%) |
Mkt cap ! $41.23M | |||
| Open | High | Low | Value | Volume |
| 17.5¢ | 18.5¢ | 17.5¢ | $18.60K | 102.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 21284 | 18.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.0¢ | 75284 | 2 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| EYE (ASX) Chart |